Paul T Spellman
Overview
Explore the profile of Paul T Spellman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
18243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ak C, Sayar Z, Thibault G, Burlingame E, Kuykendall M, Eng J, et al.
iScience
. 2024 Sep;
27(9):110668.
PMID: 39246442
Mapping the spatial interactions of cancer, immune, and stromal cell states presents novel opportunities for patient stratification and for advancing immunotherapy. While single-cell studies revealed significant molecular heterogeneity in prostate...
2.
Baker T, Lai S, Lynch A, Lesluyes T, Yan H, Ogilvie H, et al.
Cancer Discov
. 2024 Jun;
14(10):1810-1822.
PMID: 38943574
Tumors frequently display high chromosomal instability and contain multiple copies of genomic regions. Here, we describe Gain Route Identification and Timing In Cancer (GRITIC), a generic method for timing genomic...
3.
Thayer M, Heskett M, Smith L, Spellman P, Yates P
Elife
. 2024 Jun;
13.
PMID: 38896448
ASARs are a family of very-long noncoding RNAs that control replication timing on individual human autosomes, and are essential for chromosome stability. The eight known ASAR lncRNAs remain closely associated...
4.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2024 Apr;
43(4):113063.
PMID: 38578829
No abstract available.
5.
Zhang Z, Shafer A, Johnson-Camacho K, Adey A, Anur P, Brown K, et al.
J Clin Transl Sci
. 2024 Feb;
8(1):e32.
PMID: 38384895
Background: Cancer health research relies on large-scale cohorts to derive generalizable results for different populations. While traditional epidemiological cohorts often use costly random sampling or self-motivated, preselected groups, a shift...
6.
Li Z, Metzger Filho O, Viale G, DellOrto P, Russo L, Goyette M, et al.
J Clin Invest
. 2024 Feb;
134(7).
PMID: 38300710
BACKGROUNDHER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase...
7.
OBrien T, Potter A, Driscoll C, Goh G, Letaw J, McCabe S, et al.
Am J Hum Genet
. 2023 Jul;
110(8):1249-1265.
PMID: 37506692
The Healthy Oregon Project (HOP) is a statewide effort that aims to build a large research repository and influence the health of Oregonians through providing no-cost genetic screening to participants...
8.
Gurun B, Horton W, Murugan D, Zhu B, Leyshock P, Kumar S, et al.
BMC Genomics
. 2023 Jun;
24(1):349.
PMID: 37365517
T cell receptor repertoires can be profiled using next generation sequencing (NGS) to measure and monitor adaptive dynamical changes in response to disease and other perturbations. Genomic DNA-based bulk sequencing...
9.
Ren T, Chen C, Danilov A, Liu S, Guan X, Du S, et al.
bioRxiv
. 2023 Mar;
PMID: 36993424
Accurately identifying phenotype-relevant cell subsets from heterogeneous cell populations is crucial for delineating the underlying mechanisms driving biological or clinical phenotypes. Here, by deploying a learning with rejection strategy, we...
10.
Boniface C, Spellman P
Pathol Oncol Res
. 2023 Mar;
29:1611133.
PMID: 36969563
[This corrects the article DOI: 10.3389/pore.2022.1610103.].